CMN Weekly (26 January 2024) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jan. 26, 2024
News

#CRISPRMED24

Top picks

Research

Industry

CRISPR screens

Reviews

News from CRISPR Medicine News

  • At CRISPR Medicine News, we have introduced a new category in our covering of advances in CRISPR gene-editing technology: CMN Special. These are long reads based on multiple interviews with experts in a specific field. Think of them as mini-reviews where we dive deeper into a selected topic and try to educate our readers (and ourselves) about the latest discoveries and challenges. Our first shot was on delivery, and in the workings are new CMN Specials that might take a closer look at, for example, RNA editing, epigenome editing, off-targets, base editing, prime editing, infectious diseases and much more. We will strive to publish a new CMN Special approximately every month, so you can soon look forward to our next long read.
  • On Monday, we brought the first article to our new CMN Special series, Gene-Editing Tools: Delivery Methods and Challenges. Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other diseases. However, efficient, safe, and specific delivery of these tools to target cells and tissues remains a significant hurdle. We spoke with multiple gene editing experts and discussed the benefits and limitations of the available delivery technologies.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (26 January 2024) - Your Weekly CRISPR Medicine News
News: CMN Weekly (26 January 2024) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine